Market research
HOOK Hookipa Pharma Inc
NASDAQ USD Healthcare
Latest close
As of 12 Aug 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 14M
- P/E ratio
- Not available
- Analyst target
- 2
- Dividend yield
- Not available
- Beta
- 0.83
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 14M
- P/E ratio
- Not available
- Analyst target
- 2
- Dividend yield
- Not available
- Beta
- 0.83
About
About Hookipa Pharma Inc
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer. It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial. The company has a collaboration and license agreement with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis, or prevention of the hepatitis B virus (HBV) and the HIV. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.
Research context
Hookipa Pharma Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the HOOK discussion.
5 years, 7 months ago
HOOKIPA Pharma Inc is currently in a long term downtrend where the price is trading 27.7% below its 200 day moving average.
From a valuation standpoint, the stock is 98.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 18.0.
HOOKIPA Pharma Inc's total revenue rose by 42.7% to $5M since the same quarter in the previous year.
Its net income has dropped by 21.8% to $-12M since the same quarter in the previous year.
Finally, its free cash flow fell by 20.0% to $-12M since the same quarter in the previous year.
Based on the above factors, HOOKIPA Pharma Inc gets an overall score of 2/5.